Medicus Pharma has announced the commencement of the Phase II SKNJCT-004 trial for non-invasive treatment of BCC of the skin.

The CBD-based cream reduced UVA damage, preventing nuclear and mitochondrial DNA mutations associated with skin ageing and ...

Astellas and Pfizer's Xtandi plus ADT showed a decrease in mortality risk in a metastatic hormone-sensitive prostate cancer ...

At CTO West Coast, an expert discussed the implications of the FDA’s expedited approval programmes with a spotlight on ...

Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial.

Satellos said that following the Phase I data, it will be advancing its DMD small molecule to a Phase II trial.

Olezarsen is a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome and other dyslipidemia.